The International Trade Commission is a hot forum for patent disputes, but it’s almost never used by pharmaceutical companies, whose IP cases typically involve specialized fights between brand-name and generic drug makers.
That may be changing. In a novel strategy to beat back generic competition to its blockbuster cancer drug Gemzar, Eli Lilly and Co. has turned to the ITC.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]